Login / Signup

Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease.

Josuel OraAngelo CoppolaMario CazzolaLuigino CalzettaRogliani Paola
Published in: Journal of experimental pharmacology (2020)
Research on LAMA seems to have come to a standstill, the few new molecules under study do not show distinctive characteristics compared to the previous ones. Muscarinic antagonist/β2-agonist (MABAs) appear to be the major innovation currently under investigation, and they could theoretically open new research frontiers on the effect between adrenergic and muscarinic interaction in the same cell.
Keyphrases
  • chronic obstructive pulmonary disease
  • single cell
  • minimally invasive
  • cell therapy
  • stem cells
  • lung function
  • clinical trial
  • randomized controlled trial
  • muscular dystrophy
  • cystic fibrosis
  • bone marrow
  • double blind